Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · ORTHOPEDIATRICS CORP (KIDS)

OrthoPediatrics Q2 2026 revenue rose 15% to $70.5 million; net loss was $7.2 million

Mixed Impact 3 of 5 earnings Written later

OrthoPediatrics furnished an August 2026 investor presentation under Regulation FD, for use by executives in upcoming meetings with investors and analysts. The presentation shows second-quarter 2026 revenue of $70.5 million, up from $61.1 million a year earlier, but a GAAP net loss of $7.2 million, slightly wider than the $7.1 million loss in the prior-year quarter.

Key points

  • Q2 2026 revenue $70.5 million vs. $61.1 million in Q2 2025 (up 15%)
  • Q2 2026 net loss $7.2 million; GAAP diluted loss per share $0.30, unchanged from Q2 2025
  • Q2 2026 Adjusted EBITDA $6.8 million vs. $4.1 million; adjusted loss per share $0.26 vs. $0.11
  • FY2026 revenue guidance range $265.0 million to $269.0 million, 12% to 14% growth

The filing

CompanyORTHOPEDIATRICS CORP (KIDS)
Form8-K, current report
Filed with the SECAug 4, 2026, 4:31 PM ET
Accession number0001425450-26-000067

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.